| Speakers: | (1) JingYang (Peter) Xu is a second year Clinical Biochemistry fellow at the University of Saskatchewan. He completed his Bachelor of Science in Medical Laboratory Science and Bachelor of Science in Biochemistry with specialization in biomedical research at the University of Alberta, and his PhD in laboratory medicine and pathology at the University of Alberta. (2) Sisu Han is a Clinical Biochemistry Fellow with Alberta Precision Laboratories and the Department of Pathology and Laboratory Medicine at the University of Calgary. He completed his PhD in Biochemistry at the University of Toronto, where his research focused on mechanisms regulating cerebral cortex development. He subsequently completed postdoctoral training at the University of Calgary, using human brain organoid models to study the neurophysiological effects of psychedelic compounds and to support translational neuroscience research. During his Clinical Chemistry Fellowship, Dr. Han has contributed to a range of laboratory medicine projects aimed at improving laboratory quality, test utilization, workflow standardization, and patient care. His work has included point-of-care testing quality assessment, celiac disease serology harmonization, pregnancy testing evaluation, toxicology specimen assessment, and cardiac biomarker stability studies. These projects have involved retrospective data analysis, method and workflow evaluation, quality improvement approaches, and close collaboration with clinical chemists, medical laboratory technologists, and clinical teams. |
| Overviews: | (1) This lecture will describe the role of an Individualized Quality Control Plan (IQCP) in monitoring the analytical performance of devices such as blood gas analyzers. The components of an IQCP, including risk assessment, quality control planning, and quality assessment, will be discussed. Risk assessment strategies for evaluating the use of internal and external quality control (QC) measures will also be presented, along with discussion recommendations for follow-up actions. (2) This presentation will describe a local quality assessment of hemolysis in point-of-care testing venous blood gas specimens and its potential impact on potassium interpretation. Nurse-collected venous blood gas specimens were compared with phlebotomist-collected laboratory chemistry specimens using hemolysis indices, and paired patient electrolyte results were reviewed between point-of-care and central laboratory analyzers. The presentation will highlight higher hemolysis rates in blood gas specimens, patterns of potassium discordance, and the importance of interpreting point-of-care potassium results in the context of specimen quality and clinical presentation. |
| Learning Objectives: | (1) At the conclusion of this session, participants will be able to: -Briefly describe the components of Individualized Quality Control Plan (IQCP) -Outline an approach to risk assessment -Discuss practical considerations for Individualized Quality Control Plan (IQCP) (2) At the conclusion of this session, participants will be able to: -Describe the potential impact of unrecognized hemolysis on potassium results in point-of-care venous blood gas specimens -Compare hemolysis rates between nurse-collected venous blood gas specimens and phlebotomist-collected laboratory chemistry specimens -Compare sodium, potassium, and chloride dissonance patterns between point-of-care testing blood gas and central laboratory analyzer. |
Course Content
Watch webcast (May 14, 2026)
You don't currently have access to this content